After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Cytokinetics Inc is $5.17B. A total of 1.91 million shares were traded on the day, compared to an average of 1.57M shares.
In the most recent transaction, Malik Fady Ibraham sold 2,000 shares of CYTK for 43.58 per share on Mar 18 ’25. After the transaction, the EVP Research & Development now owns 140,455 company shares. In a previous transaction on Mar 17 ’25, Callos Andrew sold 2,775 shares at 44.38 per share. CYTK shares that EVP, Chief Commercial Officer owns now total 34,888.
Among the insiders who sold shares, Malik Fady Ibraham disposed of 4,389 shares on Mar 17 ’25 at a per-share price of $44.38. This resulted in the EVP Research & Development holding 101,005 shares of CYTK after the transaction. In another insider transaction, Blum Robert I sold 12,648 shares at $44.38 per share on Mar 17 ’25. Company shares held by the President & CEO now total 326,533.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, CYTK has a high of $75.71 and a low of $40.53.
As of this writing, CYTK has an earnings estimate of -$1.36 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of -$1.17 per share and a lower estimate of -$1.59.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CYTK’s latest balance sheet shows that the firm has $471.64M in Cash & Short Term Investments as of fiscal 2021. There were $269.93M in debt and $71.86M in liabilities at the time. Its Book Value Per Share was -$1.15, while its Total Shareholder’s Equity was $243.86M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CYTK is Buy with a score of 4.57.
